Építés alatt – nem éles oldal
Belépés
Befejeződött3. fázis

Estrogen and Fear in PTSD

A legfontosabb adatok

Ki végzi
The University of Texas Health Science Center, Houston
Hol
Houston és Philadelphia (Egyesült Államok)Mind a 2 helyszín megnézése
Azonosító
Állapot
Befejeződött
Fázis
3. fázis
Résztvevők
83 fő vett részt
Kezdés
2020. jún. 24.
Befejezés
2024. dec. 2.
A vizsgálat típusa
Beavatkozással járó, 2 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Estradiol
  • Placebo oral tablet
  • Prolonged Exposure (PE) therapy
A regiszteradat frissítve
2026. január 9.

Ki vehet részt

Életkor
18 év – 45 év
Nem
Csak nők
Egészséges önkéntesek
Nem vehetnek részt
A regiszter összes feltétele (20)A regiszter feltételeinek elrejtése

Ki vehet részt

  • Female, 18-45 years of age
  • Chronic (at least one month post-trauma) DSM-5 FULL PTSD diagnosis OR subPTSD diagnosis (subPTSD defined as: meeting criterion A, F, G, H, and clusters B, C, and at least 1 of the clusters D or E.)
  • CAPS-5 Past Month score ≥ 20
  • Criterion A traumatic event
  • Stable medications for 3 or more months by the time of study entrance (with the exception of benzodiazepines)
  • Women on oral contraceptives, specifically those using monophasic or biphasic of first, second, third or fourth generation with up to 35mcg of ethinyl estradiol; OR using etonogestrel / ethinyl estradiol 0.120mg/0.015mg per day vaginal ring birth control; OR using the norelgestromin / ethinyl estradiol 0.150mg/0.035mg per day transdermal patch birth control
  • Willing and able to provide informed consent

Ki nem vehet részt

  • Concurrent trauma focused psychotherapy
  • Metallic implants or devices contraindicating magnetic resonance imaging by interfering with patient safety or fMRI data collection. Cases will be cleared by the Principal Investigator and/or Baylor College of Medicine (Imaging)
  • Diagnosis of bipolar I disorder with a past year manic episode
  • Diagnosis of a psychotic disorder or psychotic symptoms that would interfere with the ability to focus on posttraumatic stress disorder (PTSD) in clinic, as determined by clinical judgment
  • Diagnosis of moderate or severe substance use disorder that would interfere with the ability to focus on posttraumatic stress disorder (PTSD) in clinic, as determined by clinical judgment
  • Cognitive impairment that would interfere with the ability to focus on posttraumatic stress disorder (PTSD) in clinic, as determined by clinical judgment
  • History of neurological disease (that involves the brain), seizure, or significant head trauma (i.e., extended loss of consciousness, neurological sequelae, or known structural brain lesion)
  • History of breast cancer or hormone-responsive cancer
  • High risk of adverse emotional or behavioral reaction, and/or an inability to understand study procedures or the informed consent process, based on investigator/clinician clinical evaluation (e.g., evidence of serious personality disorder, antisocial behavior, serious current stressors, lack of meaningful social support)
  • Suicidal ideation with imminent risk that warrants a higher level of care
  • Pregnancy (to be ruled out by urine ß-HCG)
  • Use of benzodiazepines
  • Self-injurious behavior that involves suicidal intent, requires medical attention, or occurs daily

Helyszínek itt: Egyesült Államok

  • The University of Texas Health Science Center at Houston (UTHealth Houston)Houston, Egyesült Államok
  • University of Pennsylvania Perelman School of MedicinePhiladelphia, Egyesült Államok

A vizsgálatról

Mit akar kideríteni a vizsgálat

The purpose of this research study is to determine if taking a pill of estradiol (E2) together with prolonged exposure (PE) therapy can improve this treatment outcome in women diagnosed with Post-Traumatic Stress Disorder (PTSD). 80 subjects will take part in this research study across UTHealth Houston and UPenn (40 subjects at each site). Participants will be randomized into one of two groups, PE + E2 or PE + placebo. The study will include preliminary screening and baseline visits, experimental visits, and therapy visits over the course of six weeks. Several follow-up visits will take place.

A vizsgálat 2 csoportja

  • Prolonged Exposure (PE) therapy with EstradiolA vizsgált kezelés

    A single 2mg dose of estradiol (a form of estrogen) will be taken at home by the study participant 5-6 hours before each of 5 prolonged exposure (PE) therapy treatment sessions (sessions 2 to 6). PE therapy is a validated treatment for PTSD.

    Kezelés: Estradiol és Prolonged Exposure (PE) therapy

  • Prolonged Exposure (PE) therapy with PlaceboPlacebo, összehasonlításként

    A single 2mg placebo pill will be taken at home by the study participant 5-6 hours before each of 5 prolonged exposure (PE) therapy treatment sessions (sessions 2 to 6). PE therapy is a validated treatment for PTSD.

    Kezelés: Placebo oral tablet és Prolonged Exposure (PE) therapy

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
A Randomized, Double-blind Placebo-controlled Multi-center Study of Identifying Neural Mechanisms of PTSD Symptom Reduction Induced by Combined Estrogen and Prolonged Exposure Therapy
A regiszteradat frissítve
2026. január 9.